Bone marrow fibrosis and vascular density lack prognostic significance in childhood acute lymphoblastic leukaemia
Three recent papers by Norén-Nyström et al. [1] [2] [3] have collectively shown that higher levels of bone marrow fibrosis (measured as reticulin fibrin density (RFD)) and increased vascularity (microvessel density (MVD)) are associated with both relapse and higher minimal residual disease (MRD) in precursor B acute lymphoblastic leukaemia. Other studies have reported marrow fibrosis 4 or increased vascularity 5 in some acute lymphoblastic leukaemia (ALL) patients, but have not found a prognostic significance associated with higher levels.
To resolve this controversy and to determine whether RFD and/or MVD has a clinically useful prognostic role in our patients, we measured fibrosis, RFD and MVD in the 84 patients diagnosed with ALL between 2001-2007 at our institute who had good-quality biopsies and compared them with known sensitive prognostic markers, such as chromosome ploidy and MRD. The patients had been treated according to study 7 (before 2003, 24 patients, 5 relapses) or study 8 (55 patients, 8 relapses) of the Australian and New Zealand Children's Haematology and Oncology Group, or by some other therapy (5 patients). There is currently no difference in leukaemia-free survival between the two Berlin-Frankfurt-Munster (BFM)-based protocols at our centre; therefore, it seemed reasonable to analyse the patients as a group. The 84 patients included 44 males and 40 females who ranged in age from 11 months to 17 years with a median age of 5 years.
New trephine sections were cut and stained for reticulin fibrosis, collagen fibrosis and von Willebrand factor (VWF) immunohistochemistry. 6 A hematoxylin and eosin (H&E) stain was performed to facilitate the determination of cellularity. The bone marrow fibre content was determined by using a grading system (modified Bauermeister scale) that included five grades. 7 The percentages of patients with different grades of fibrosis were grade 0: 2.5%, grade 1: 33.3%, grade 2: 37%, grade 3: 19.7% and grade 4 (collagen þ ): 7.5%. RFD was quantified as previously described by Norén-Nyströ m et al. 1 Briefly, RFD was calculated using a 121-point eye piece graticule at Â 400 magnification. The intersections of reticulin fibres with the crossing points of the graticule were counted in 10 different areas in the section. RFD was defined as volume of reticulin fibres per volume reference tissue. Fibrosis grade showed a strong positive correlation with RFD (Po0.001).
In keeping with earlier reports, 3 RFD was significantly higher in precursor B acute lymphoblastic leukaemia cases than in T-ALL (Table 1) and there was a negative correlation between RFD and white blood cell count at diagnosis, with high RFD being associated with lower initial white blood cell count: mean 10.7 vs 35.3 Â 10 9 /l for lower RFD values. Similarly, there was a negative correlation between RFD and the percentage of blast cells in the peripheral blood (Spearman's correlation r ¼ À0.278, P ¼ 0.018). A higher RFD was also correlated with a higher cellularity in the bone marrow (r ¼ 0.292, P ¼ 0.007). This could imply that some types of leukaemia create a higher degree of fibrosis than others and that these blasts are then 'trapped' in the marrow.
We found no difference between the RFD values of NCI (National Cancer Institute risk score) high-or low-risk patients, or between patients who relapsed vs those who continue in complete remission (Table 1 ). The most important prognostic factor in our patients was MRD. PCR-based MRD analysis was performed on day 33 and 79 in study 8 patients, that is, at the Letters to the Editor end of induction and just after consolidation as per the BFM ALL guidelines, 8 and at several time points including day 35, but not day 79, in study 7. 9 Patients who had low MRD (o1 Â 10 À3 ) at the end of induction had fewer relapses (15%) compared with 56% for those with high MRD (41 Â 10 À3 ) (Spearman's log rank Po0.0012). In our series, RFD showed no correlation with MRD levels (Table 1) .
Cytogenetic subgroups showed significant differences in RFD values, but the groups were small and it was difficult to interpret these results when, for example, patients with t(12;21) had low RFD levels, whereas those with trisomies 4, 10 and 17 had much higher RFD levels. There was an almost linear increase in RFD from hypodiploid to high-hyperdiploid cases (Table 1) .
MVD was also analysed for these patients using 4 mm paraffin sections, which were stained with an antibody to von Willebrand factor (DakoCytomation, Glostrup, Denmark) to identify micro-vessels. Micro-vessel hot spots were identified and MVD measured in three independent areas at a magnification of x400 in a square lattice representing 0.06 mm 2 . The only difference with the measurements as described by Norén-Nyströ m et al. was that, although vessel fragments or buds that stained positively with anti-VWF were included in their measurement of MVD, we only counted structures as micro-vessels if a lumen was clearly identified and the size did not exceed 10 mm.
Unlike the cohort examined by Norén-Nyströ m et al., 3 the group of patients who subsequently relapsed in our study had an almost identical MVD value to that of the group who remained in remission, and there was no statistical difference in MVD between T-ALL and precursor B acute lymphoblastic leukaemia or within the other groupings (Table 1) . Linear regression analysis of RFD and MVD failed to show a correlation between these two variables (P ¼ 0.442), similar to Norén-Nyströ m's finding. 3 As Norén-Nyströ m et al. 3 had reported poorer outcomes in ALL patients with both a high MVD and a high RFD, we performed a similar analysis. Patients with both MVD and RFD values above the respective 75% level of measurement were placed in the 'high' group (15 patients, 0 events), whereas all the others were placed in the 'low' group (62 patients, 13 events). Kaplan-Meier analysis showed no statistical difference in leukaemia-free survival (P ¼ 0.108).
There is no doubt that both marrow fibrosis and increased vascular density are important features of presentation ALL and that with therapy their density reduces, in line with marrow recovery. 2 The seemingly contradictory findings regarding their prognostic significance most likely reflect a weak or indirect effect on outcome compared with direct measures of response to therapy, such as MRD. If anything, higher RFD was more likely to be associated with better conventional risk factors, such as lower initial white blood cell count, precursor B-rather than T-cell phenotype and hyperploidy. Finding an increased MVD at diagnosis may become more important when anti-angiogenic drugs are adopted for treating subsets of high-risk patients. Further research into cellular and molecular interactions is needed to clarify the biological significance of RFD and MVD, but at this stage, it seems that measurement of RFD and MVD does not add to our ability to identify patients with poor prognostic outcomes in BFM-style protocols.
